July 27, 2021

BIOHIT supplies rapid turbidimetric GI test kits

BIOHIT HealthCare Ltd is now distributing three new particle enhanced turbidimetric immunoassays (PETIAs) for the rapid and differential diagnosis of gastrointestinal (GI) diseases. The new product line from IDK® – TurbiCAL®, TurbiFIT® and TurbiPEL® – can be used to detect key biomarkers calprotectin, haemoglobin and pancreatic elastase in patient stool samples far more quickly than their ELISA equivalents, using existing clinical chemistry analysers. The rapid turbidimetry technology relies on agglutination reactions between antigens and their complementary antibodies – monoclonal for TurbiCAL and TurbiPEL, polyclonal for TurbiFIT – coated onto latex particles, and shows good correlation to corresponding ELISA technologies.


All three parameters can be determined from one single stool sample extract using the unique IDK TurbiTUBE, designed exclusively for IDK turbidimetric assays. The TurbiTUBE, which can be loaded directly onto the analyser, allows easy, clean and precise preparation of the stool sample extracts using a universal extraction buffer.


TurbiCAL allows the timely differential diagnosis between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), and is also used to closely monitor intestinal inflammation and disease activity in IBD patients. TurbiCAL therefore helps diagnose bowel inflammation quickly, minimise bowel damage and expedite treatment. TurbiPEL, on the other hand, can be used to identify exocrine pancreatic insufficiency and to monitor the levels of digestive enzymes that these patients produce. TurbiFIT detects traces of blood in stool (faecal occult blood), which serves as a preliminary screening test for colorectal cancer in asymptomatic patients, as well as a test for possible bowel diseases in patients with lower abdominal symptoms.


The kits are available as 100, 200 and 800 test kit packages, and include ready-to-use reagents, as well as supporting materials that guide the user through different protocols. These new turbidimetric GI tests extend and complement BIOHIT’s repertoire of diagnostic and monitoring kits for gastroenterology.


For more information, visit www.biohithealthcare.co.uk/faecaltests


About BIOHIT HealthCare Ltd

BIOHIT HealthCare Ltd (www.biohithealthcare.co.uk) is part of the Finnish public company, BIOHIT OYJ, which specialises in the development, manufacture and marketing of products and analysis systems for the early diagnosis and prevention of gastrointestinal diseases. The company’s many unique and patented diagnostic tests transform clinical practice and make screening, diagnosis and monitoring of gastrointestinal diseases efficient and cost effective. Non-invasive diagnostics are at the core of BIOHIT’s offering, making it the provider of choice for leading gastroenterologists and laboratory scientists worldwide.

Keep reading

January 26, 2022

Knowledge is power

  Jason Wakefield, Sales Director at Todd Research   Many event managers and venue owners believe that simply...

Read more
January 25, 2022

Bring in the new year with a puppy and bite-sized science

I may be MD of kdm, but I am quick to jump in and remind members of the...

Read more
January 19, 2022

Study confirms accuracy of new generation GastroPanel® test for non-invasive diagnosis of atrophic gastritis and Helicobacter pylori infection

A clinical validation study conducted at Oulu University Hospital (OUH) has confirmed the high accuracy of BIOHIT Oyj’s...

Read more